Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_00200 |
| Species: | Homo sapiens |
| Position : | chr2:178806313-178806949 |
| Year: | 2024 |
| Title: | Regulation of sarcomere formation and function in the healthy heart requires a titin intronic enhancer. |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | dilated cardiomyopathy |
| PMID: | 39688912 |
| MONDO: | MONDO:0005021 |
| Tissue: | heart |
| Tissue Ontology ID: | UBERON:0000948 |
| Cell Source: | human induced pluripotent stem cell-derived cardiomyocytes |
| Cell Type: | cardiac muscle cell |
| Cell Ontology ID: | CL:0000746 |
| Experiment Type: | Enhancer activity assay; endogenous enhancer perturbation; TF motif functional assay; target-gene expression assay; phenotypic assay; TF binding assay; Disease-variant functional analysis; In vivo functional validation |
| High Throughput Method: | ATAC-seq; MPRA; single-nucleus RNA-seq |
| Low Throughput Method: | CRISPR/Cas9 E0/E1 deletion; GFP reporter assay; MEF2-site mutagenesis; transgenic mouse reporter assay; RT-qPCR; Western blot; sarcomere analysis; engineered cardiac microtissue contractility assay; Site-directed/motif mutagenesis; Allele-specific reporter assay; Mouse genetic deletion/knock-in; In vivo phenotyping |
| Target gene : | TTN |
| TF name : | NA |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_00001 | chr2:178806313-178806949 | heart | cardiac muscle cell | dilated cardiomyopathy |
| E_00002 | chr2:178806313-178806949 | heart | cardiac muscle cell | dilated cardiomyopathy |
| E_00052 | chr2:178806313-178806949 | heart | cardiac muscle cell | NA |
| E_00154 | chr2:178806313-178806949 | heart | cardiac muscle cell | dilated cardiomyopathy |
| E_00387 | chr2:178806313-178806949 | heart | cardiac muscle cell | dilated cardiomyopathy |